NeuBase Therapeutics Inc

NASDAQ:NBSE  
1.03
+0.06 (+6.77%)
Earnings Announcements

NeuBase Therapeutics Reports Results For The Second Quarter Of Fiscal Year 2022

Published: 05/12/2022 21:27 GMT
NeuBase Therapeutics Inc (NBSE) - Neubase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022.
Q2 Loss per Share $0.30.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.26

More details on our Analysts Page.